{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:06:33Z","timestamp":1787025993770,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40265-023-01947-9","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:03:46Z","timestamp":1697432626000},"page":"1537-1541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Lotilaner Ophthalmic Solution 0.25%: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/OPTO.S142708","volume":"10","author":"SR Fromstein","year":"2018","unstructured":"Fromstein SR, Harthan JS, Patel J, et al. Demodex blepharitis: clinical perspectives. Clin. Optom. 2018;10:57\u201363.","journal-title":"Optom"},{"issue":"8","key":"1947_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/ICL.0000000000001003","volume":"49","author":"MK Rhee","year":"2023","unstructured":"Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311\u20138.","journal-title":"Eye Contact Lens"},{"key":"1947_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/OPTH.S399989","volume":"17","author":"M Farid","year":"2023","unstructured":"Farid M, Ayres BD, Donnenfeld E, et al. Delphi panel consensus regarding current clinical practice management options for Demodex blepharitis. Clin Ophthalmol. 2023;17:667\u201379.","journal-title":"Clin Ophthalmol"},{"key":"1947_CR4","unstructured":"Tarsus Pharmaceuticals. FDA Approves XDEMVY\u2122 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis [media release]. 25 Jul 2023. https:\/\/ir.tarsusrx.com\/news-releases\/news-release-details\/fda-approves-xdemvytm-lotilaner-ophthalmic-solution-025."},{"key":"1947_CR5","unstructured":"Tarsus Pharmaceuticals. XDEMVY\u2122 (lotilaner ophthalmic solution) 0.25%, for topical ophthalmic use: US prescribing information. 2023. https:\/\/tarsusrx.com\/wp-content\/uploads\/XDEMVY-Prescribing-Information-24JUL23.pdf. Accessed 28 Aug 2023."},{"issue":"1","key":"1947_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvp.12959","volume":"45","author":"X Zhou","year":"2022","unstructured":"Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasiticides used in veterinary medicine. J Vet Pharmacol Ther. 2022;45(1):1\u201315.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"1947_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbrc.2009.11.131","volume":"391","author":"Y Ozoe","year":"2010","unstructured":"Ozoe Y, Asahi M, Ozoe F, et al. The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels. Biochem Biophys Res Commun. 2010;391(1):744\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1947_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3862684","author":"R Gonzalez-Salinas","year":"2021","unstructured":"Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Safety and efficacy of topical lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis: a pilot study. J Ophthalmol. 2021. https:\/\/doi.org\/10.1155\/2021\/3862684.","journal-title":"J Ophthalmol"},{"issue":"8","key":"1947_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/jop.2021.0011","volume":"37","author":"R Gonzalez-Salinas","year":"2021","unstructured":"Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Collarette elimination and Demodex mite eradication with topical lotilaner ophthalmic solution, 0.25. J Ocul Pharmacol Ther. 2021;37(8):479\u201384.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"1947_CR10","doi-asserted-by":"publisher","first-page":"101492","DOI":"10.1016\/j.clae.2021.101492","volume":"45","author":"R Gonzalez-Salinas","year":"2022","unstructured":"Gonzalez-Salinas R, Karpecki P, Yeu E, et al. Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation: a randomized, controlled, double-masked clinical trial. Cont Lens Anterior Eye. 2022;45(4):101492.","journal-title":"Cont Lens Anterior Eye"},{"key":"1947_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2093755","author":"E Yeu","year":"2022","unstructured":"Yeu E, Holdbrook M, Baba SN, et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle. Ocul Immunol Inflamm. 2022. https:\/\/doi.org\/10.1080\/09273948.2022.2093755.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1947_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/ICO.0000000000003097","volume":"42","author":"E Yeu","year":"2023","unstructured":"Yeu E, Wirta DL, Karpecki P, et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2023;42(4):435\u201343.","journal-title":"Cornea"},{"key":"1947_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.05.030","author":"IB Gaddie","year":"2023","unstructured":"Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). Ophthalmology. 2023. https:\/\/doi.org\/10.1016\/j.ophtha.2023.05.030.","journal-title":"Ophthalmology"},{"issue":"9","key":"1947_CR14","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1167\/iovs.05-0275","volume":"46","author":"YY Gao","year":"2005","unstructured":"Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089\u201394.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1947_CR15","doi-asserted-by":"crossref","unstructured":"Sadri E, Castillo RM, Jalalat P. Long term safety of lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis: Saturn 1 extension study [slide deck]. In: American Society of Cataract and Refractive Surgery Annual Meeting. 2023.","DOI":"10.1097\/ICO.0000000000003484"}],"updated-by":[{"DOI":"10.1007\/s40265-023-01965-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01947-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:15:00Z","timestamp":1730312100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":15,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01947-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"16 October 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01965-7","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01965-7","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}